CellCarta Executive and Leadership Team

Dusty Tenney, the Chief Executive Officer at CellCarta, directs the overarching corporate strategy and global expansion initiatives for the organization. Tenney architects long-term growth plans by aligning biomarker platform capabilities with the evolving needs of the biopharmaceutical industry. By fostering partnerships with major research institutions, the Chief Executive Officer ensures the company maintains a competitive edge in precision medicine. Dusty Tenney oversees the integration of new laboratory services across international markets, driving operational efficiency and scientific innovation. This leadership role involves constant collaboration with the Board to secure capital investments and prioritize research development. Through rigorous oversight of organizational performance, the Chief Executive Officer guarantees that all laboratory operations meet the highest standards of quality and regulatory compliance. Ultimately, Tenney secures the market position of the firm as a premier provider of specialized testing services for complex clinical trials.

Anthony Mattacchione, the Global Chief Financial Officer at CellCarta, directs the financial planning, reporting, and capital allocation strategies for the entire organization. Mattacchione oversees the fiscal health of the company by monitoring revenue streams from diverse biomarker service lines and international laboratory operations. By managing complex budgetary requirements, the Global Chief Financial Officer ensures sufficient funding for research and development projects. Anthony Mattacchione coordinates with executive leadership to evaluate potential acquisitions and strategic investments that expand the global footprint of the firm. This leadership role involves rigorous analysis of market trends to optimize pricing models for precision medicine services. Through the implementation of robust financial controls, the Global Chief Financial Officer maintains transparency and accountability across all departments. Mattacchione drives sustainable growth by aligning financial resources with the core mission of providing high-quality, customized testing solutions to the global biopharmaceutical sector.

Louis Norton, the Chief Information Officer at CellCarta, manages the digital infrastructure and data security protocols essential for high-throughput biomarker research. Norton designs scalable cloud-based systems that support the massive data requirements of global clinical trials. By implementing advanced cybersecurity frameworks, the Chief Information Officer protects sensitive patient information and proprietary research data across all laboratory sites. Louis Norton drives the digital transformation of laboratory workflows, ensuring seamless integration between diagnostic platforms and client reporting systems. This role requires constant coordination with the technology team to optimize data processing speeds and analytical accuracy. Through the deployment of sophisticated software solutions, the Chief Information Officer enhances the overall efficiency of the research organization. Norton maintains the integrity of the digital ecosystem, allowing the company to deliver precise, data-driven insights to biopharmaceutical partners operating in diverse geographic regions.

Ehab ElGabry, the Chief Medical Officer at CellCarta, provides clinical leadership and scientific guidance for all biomarker testing platforms. ElGabry oversees the medical integrity of research protocols, ensuring that laboratory services meet the stringent requirements of clinical trials and regulatory bodies. By directing the scientific team, the Chief Medical Officer validates the accuracy and clinical relevance of diagnostic assays used in precision medicine. Ehab ElGabry collaborates with biopharmaceutical partners to design customized testing solutions that address specific therapeutic challenges. This role involves monitoring emerging medical trends to ensure the company remains at the forefront of scientific innovation. Through the supervision of clinical data interpretation, the Chief Medical Officer guarantees that all research outputs provide actionable insights for drug development. ElGabry maintains high standards of medical excellence, supporting the company in delivering reliable, high-impact results for complex research programs across North American and international markets.